Prostate Cancer Clinical Trials

• adults ≥ 18 years of age.

• ECOG performance status of 0 to 2.

• histopathological and/or cytological confirmation of adenocarcinoma of the prostate.

• PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,

• castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L).

• Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after \[177Lu\]Lu-PSMA targeted therapy.

• ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization

• eGFR as requested by the sponsor